As pharmacy benefit managers come under greater scrutiny for their role in rising drug costs, Republican leaders of the House Energy and Commerce Committee asked the Federal Trade Commission to investigate past mergers that led three companies to dominate the behind-the-scenes middlemen in the pharmaceutical supply chain.

In a July 27 letter, the lawmakers cite ongoing debate over the extent to which pharmacy benefit managers may dampen or accelerate the prices that insured consumers pay for their medicines. Also known as PBMs, these companies negotiate with drug makers for favorable placement on lists of insured medicines, or formularies, which are used by health plans and employers.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • Another sing and dance by the legislators as they are in PBMs hip pocket. Just trying to fool US population that they are doing something. Cow has been slaughtered, cooked and served and they are asking who slaughtered. Were they sleeping?

    Hypocrites of the finest order. πŸ‘πŸ‘πŸ‘πŸ‘πŸ‘πŸ‘

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy